FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML

Retrieved on: 2024-09-18 22:15:18

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. View article details on hiswai:

Excerpt

ICT01 is a humanized anti-butyrophilin (BTN) 3A monoclonal antibody. The phase 1/2a EVICTIONtrial (NCT04243499) is evaluating ICT01. ICT01 plus ...

Article found on: www.targetedonc.com